WALTHAM, MA - April 23, 2026 - - KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug ...
US FDA approves Sanofi's Tzield to delay the onset of stage 3 type 1 diabetes in young children: Paris Friday, April 24, 2026, 11:00 Hrs [IST] The US Food and Drug Administration ...
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit ...
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high ...
The FDA has approved an expanded indication for the CD3-directed monoclonal antibody teplizumab-mzwv to delay stage 3 type 1 ...
Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. Expanded approval includes children aged one year and above with stage 2 T1D to ...
Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...
Health and Me on MSN
Type 1 diabetes: US FDA expands Sanofi’s Tzield to treat children aged 1
Tzield is a CD3-directed monoclonal antibody drug that was first approved in the US in November 2022 to delay the onset of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results